about
Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapyContext-Dependent Cell Cycle Checkpoint Abrogation by a Novel Kinase InhibitorNon ionising radiation as a non chemical strategy in regenerative medicine: Ca(2+)-ICR "In Vitro" effect on neuronal differentiation and tumorigenicity modulation in NT2 cellsAurora-A kinase is essential for bipolar spindle formation and early developmentAurora A is essential for early embryonic development and tumor suppressionNF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy targetAurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast CancerEsophageal adenocarcinoma: treatment modalities in the era of targeted therapy.Antagonists of anaphase-promoting complex (APC)-2-cell cycle and apoptosis regulatory protein (CARP)-1 interaction are novel regulators of cell growth and apoptosis.Integration of gene expression data with prior knowledge for network analysis and validation.Association between genetic polymorphisms in AURKA (rs2273535 and rs1047972) and breast cancer risk: a meta-analysis involving 37,221 subjects.New therapeutic targets in soft tissue sarcoma.3,6,2',4',5'-Pentahydroxyflavone, an orally bioavailable multiple protein kinase inhibitor, overcomes gefitinib resistance in non-small cell lung cancer.AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues.Identification of an Aurora kinase inhibitor specific for the Aurora B isoform.Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.Update on aurora kinase inhibitors in gynecologic malignancies.Understanding cytokinesis failure.The role of DNA synthesis imaging in cancer in the era of targeted therapeuticsUpdate on Aurora Kinase Targeted Therapeutics in Oncology.Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitorsCucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cellsTranscriptomic characterization of fibrolamellar hepatocellular carcinoma.Discovery of benzo[e]pyridoindolones as kinase inhibitors that disrupt mitosis exit while erasing AMPK-Thr172 phosphorylation on the spindle.The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing.Bioorthogonal imaging of aurora kinase A in live cellsGene expression in sheep carotid arteries: major changes with maturational development.Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells.USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinaseA Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma.Working hard for recovery: mitotic kinases in the DNA damage checkpointIn vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemiaAurora kinase inhibitors: identification and preclinical validation of their biomarkers.Target validation and biomarker identification in oncology : the example of aurora kinases.Identification of novel small molecule inhibitors of centrosome clustering in cancer cells
P2860
Q21245716-FD91FEA1-70C0-4200-9791-0198CD8AB1B9Q27665373-9209B924-C311-480F-B2A7-A7578E53C02FQ28486085-9895F5E9-0D16-460D-97C9-D468CB761A04Q28506140-B3AE853D-9E2A-4FB2-94E9-9059866D54E7Q28590685-A72D4331-5AFF-4396-A417-3C38E7334E4FQ28611413-140691BD-FFC5-4E3C-B733-24BE550B8D2CQ30487026-54DCEEAC-1150-4E19-BB69-26C6369A9C8EQ33680293-CFAB9104-BAB6-4685-BC62-193531C54C3FQ33932460-A631D2A4-B4F9-499F-A169-AF5E7552F80EQ34014334-4A121A4A-C6AB-40C5-9B0F-95B3C49C1B4AQ34085061-7EEE1575-8E4A-40E4-83A5-4360326FDE40Q34235395-636A8B3F-9099-4A5C-B23B-3997E1C08C4DQ34267924-F2D3158D-1A4C-44EB-81BF-0BCE1D90A391Q34317305-58A54497-997A-4732-9156-520A81F47DCEQ34459957-1AFBA353-4AEA-4AAE-9FC6-22FF8CE315E2Q34464172-961D3C74-D675-45FB-A9E4-3D48123F6FFBQ34498390-217C01A2-A5F1-443C-AA25-425FD0905656Q34576017-4E228BB8-DECB-4A84-A600-B023124E6A87Q34717820-855DCBB9-247B-42FE-B0EC-8EF9E1E88843Q34907192-1D6C4B48-9446-42BE-A0E4-D1970FB2F9A1Q34941504-D99D633F-8A3C-4BFA-A7A5-B1CB8A4FF61BQ34982418-1DABC980-417A-4B74-8FD3-DFB51201004FQ35178065-8BF65EA0-E218-4A9D-BDCD-E0E1415FEDB8Q35691904-29620481-77FD-4E29-88BE-AB4F6F536710Q36214610-E346A5A5-87B0-4CEC-9991-83ED34AF09AEQ36268536-EA6F622A-FE2B-4017-B15F-30260618300DQ36355904-B0D1AD40-9D51-451F-8AAF-809CA360C653Q36451580-8EC79108-892C-4416-A926-85E353723958Q36470833-D2633A1A-E0A2-48CD-A2ED-D54CF33FDDF5Q36492204-90617168-E3CD-4988-930C-E1401E6142D9Q36511204-B477688E-49D0-4A13-A5FE-A759A2C9941BQ36700778-F75A3029-4CE0-4BA5-8C12-BD7F42A27D18Q36747293-14B1A312-0E14-4573-81B1-415A5B28EF77Q36763982-AC0E6D7A-B554-4E14-A939-CE6F494F5685Q36811636-85B13220-3E3A-4F6F-9A39-BA62B0D9A1D9Q36902187-279CA8F7-3F0A-4A4E-A235-41500C3A0233Q36915927-7CE2A797-1BCE-49B3-948B-C385B53D6418Q37030878-58EF900A-401A-4302-B170-632F8B7C94ADQ37141995-54F92177-4319-4ACD-98B8-090E8B992737Q37381616-6F938D0C-7ABE-4C5B-A564-9C69B4D98DBA
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Aurora kinases: new targets for cancer therapy.
@ast
Aurora kinases: new targets for cancer therapy.
@en
Aurora kinases: new targets for cancer therapy.
@nl
type
label
Aurora kinases: new targets for cancer therapy.
@ast
Aurora kinases: new targets for cancer therapy.
@en
Aurora kinases: new targets for cancer therapy.
@nl
prefLabel
Aurora kinases: new targets for cancer therapy.
@ast
Aurora kinases: new targets for cancer therapy.
@en
Aurora kinases: new targets for cancer therapy.
@nl
P2093
P1476
Aurora kinases: new targets for cancer therapy.
@en
P2093
Archie Tse
Gary K Schwartz
Richard D Carvajal
P304
P356
10.1158/1078-0432.CCR-06-1405
P407
P577
2006-12-01T00:00:00Z